Infections in Patients With Moderate to Severe Psoriasis Treated With Ixekizumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Infections From 7 Clinical Trials of Ixekizumab, an Anti-Interleukin-17A Monoclonal Antibody, in Patients With Moderate-to-Severe Psoriasis
Br J Dermatol 2017 Jun 10;[EPub Ahead of Print], KA Papp, H Bachelez, A Blauvelt, KL Winthrop, R Romiti, M Ohtsuki, N Acharya, DK Braun, L Mallbris, F Zhao, W Xu, CD Walls, B StroberFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.